Related references
Note: Only part of the references are listed.Copper chelation in patients with hypertrophic cardiomyopathy
Anna Reid et al.
OPEN HEART (2022)
Prognostic significance of cardiac magnetic resonance-based markers in patients with hypertrophic cardiomyopathy
Zsofia Dohy et al.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2021)
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
John A. Spertus et al.
LANCET (2021)
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto et al.
LANCET (2020)
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Steve R. Ommen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications
Betty Raman et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2019)
When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts
Janus Christian Jakobsen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy Under-Recognized Subset of Candidates for Heart Transplant
Ethan J. Rowin et al.
CIRCULATION-HEART FAILURE (2014)
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
Perry M. Elliott et al.
EUROPEAN HEART JOURNAL (2014)
Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment
Jun Lu et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats
Lin Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Mechanisms of disease: hypertrophic cardiomyopathy
Norbert Frey et al.
NATURE REVIEWS CARDIOLOGY (2012)
Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimer's Disease
Garth J. S. Cooper
DRUGS (2011)
Research Priorities in Hypertrophic Cardiomyopathy Report of a Working Group of the National Heart, Lung, and Blood Institute
Thomas Force et al.
CIRCULATION (2010)
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study
G. J. S. Cooper et al.
DIABETOLOGIA (2009)
A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes
D. Gong et al.
DIABETOLOGIA (2008)
Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator
Mia Jullig et al.
PROTEOMICS CLINICAL APPLICATIONS (2007)
Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats
Deming Gong et al.
MOLECULAR PHARMACOLOGY (2006)
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction
Martin S. Maron et al.
CIRCULATION (2006)
Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy
Kevin M. Harris et al.
CIRCULATION (2006)
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy
I Olivotto et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation - Quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals
GJS Cooper et al.
DIABETES (2005)
Regeneration of the heart in diabetes by selective copper chelation
GJS Cooper et al.
DIABETES (2004)
Role of oxidative stress in myocardial hypertrophy and failure
DB Sawyer et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2002)
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
PM Elliott et al.
LANCET (2001)
Share Paper
